BACKGROUND: Although adherence to antiretroviral therapy may be higher in sub-Saharan Africa, knowledge regarding the magnitude of adherence needed to maintain virological suppression in this setting is limited. METHODS: A case-control study among HIV-infected individuals initiating highly active antiretroviral therapy (HAART) in Gaborone, Botswana, was performed. Cases were randomly selected from subjects on HAART > or =6 months with plasma HIV-1 RNA levels (viral loads) >1000 copies/mL. Controls were randomly selected from subjects on HAART > or =6 months with all viral loads <400 copies/mL. HAART adherence was determined using pharmacy refill records. RESULTS: In total, 302 individuals were included; 57 cases were compared with 245 controls with respect to adherence levels on nonnucleoside reverse transcriptase inhibitor-based HAART. Median adherence levels, as measured using pharmacy refill patterns, were consistently high but differed among cases and controls (91%, interquartile range 83%-97% for cases vs 97%, interquartile range 91%-100% for controls, P < 0.001, rank-sum test). Adherence <95% was independently associated with virological failure (odds ratio 4.19, 95% confidence interval 2.2 to 8.3). CONCLUSIONS: Very high rates of adherence were present in this setting, yet virological failure occurred nonetheless. Future work should explore other factors that might explain treatment failure in the setting of high levels of adherence.
BACKGROUND: Although adherence to antiretroviral therapy may be higher in sub-Saharan Africa, knowledge regarding the magnitude of adherence needed to maintain virological suppression in this setting is limited. METHODS: A case-control study among HIV-infected individuals initiating highly active antiretroviral therapy (HAART) in Gaborone, Botswana, was performed. Cases were randomly selected from subjects on HAART > or =6 months with plasma HIV-1 RNA levels (viral loads) >1000 copies/mL. Controls were randomly selected from subjects on HAART > or =6 months with all viral loads <400 copies/mL. HAART adherence was determined using pharmacy refill records. RESULTS: In total, 302 individuals were included; 57 cases were compared with 245 controls with respect to adherence levels on nonnucleoside reverse transcriptase inhibitor-based HAART. Median adherence levels, as measured using pharmacy refill patterns, were consistently high but differed among cases and controls (91%, interquartile range 83%-97% for cases vs 97%, interquartile range 91%-100% for controls, P < 0.001, rank-sum test). Adherence <95% was independently associated with virological failure (odds ratio 4.19, 95% confidence interval 2.2 to 8.3). CONCLUSIONS: Very high rates of adherence were present in this setting, yet virological failure occurred nonetheless. Future work should explore other factors that might explain treatment failure in the setting of high levels of adherence.
Authors: Evan Wood; Robert S Hogg; Benita Yip; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner Journal: J Acquir Immune Defic Syndr Date: 2004-03-01 Impact factor: 3.731
Authors: David W Haas; Heather J Ribaudo; Richard B Kim; Camlin Tierney; Grant R Wilkinson; Roy M Gulick; David B Clifford; Todd Hulgan; Catia Marzolini; Edward P Acosta Journal: AIDS Date: 2004-12-03 Impact factor: 4.177
Authors: Jean B Nachega; Michael Hislop; David W Dowdy; Melanie Lo; Saad B Omer; Leon Regensberg; Richard E Chaisson; Gary Maartens Journal: J Acquir Immune Defic Syndr Date: 2006-09 Impact factor: 3.731
Authors: Jean B Nachega; Michael Hislop; David W Dowdy; Richard E Chaisson; Leon Regensberg; Gary Maartens Journal: Ann Intern Med Date: 2007-04-17 Impact factor: 25.391
Authors: Evan Wood; Robert S Hogg; Benita Yip; Mark W Tyndall; Christopher H Sherlock; Richard P Harrigan; Michael V O'Shaughnessy; Julio S G Montaner Journal: J Acquir Immune Defic Syndr Date: 2002-06-01 Impact factor: 3.731
Authors: Patrice Severe; Paul Leger; Macarthur Charles; Francine Noel; Gerry Bonhomme; Gyrlande Bois; Erik George; Stefan Kenel-Pierre; Peter F Wright; Roy Gulick; Warren D Johnson; Jean William Pape; Daniel W Fitzgerald Journal: N Engl J Med Date: 2005-12-01 Impact factor: 91.245
Authors: S Staszewski; J Morales-Ramirez; K T Tashima; A Rachlis; D Skiest; J Stanford; R Stryker; P Johnson; D F Labriola; D Farina; D J Manion; N M Ruiz Journal: N Engl J Med Date: 1999-12-16 Impact factor: 91.245
Authors: Julian Harris; Mara Pillinger; Deborah Fromstein; Bayardo Gomez; Ivelisse Garris; Peter A Kanetsky; Pablo Tebas; Robert Gross Journal: AIDS Behav Date: 2011-10
Authors: Kartik K Venkatesh; A K Srikrishnan; Kenneth H Mayer; N Kumarasamy; Sudha Raminani; E Thamburaj; Lakshmi Prasad; Elizabeth W Triche; Suniti Solomon; Steven A Safren Journal: AIDS Patient Care STDS Date: 2010-11-22 Impact factor: 5.078
Authors: Edwin Masese Machine; Susan L Gillespie; Nuria Homedes; Beatrice J Selwyn; Michael W Ross; Gabriel Anabwani; Gordon Schutze; Mark W Kline Journal: AIDS Care Date: 2016-05-10
Authors: James H McMahon; Michael R Jordan; Karen Kelley; Silvia Bertagnolio; Steven Y Hong; Christine A Wanke; Sharon R Lewin; Julian H Elliott Journal: Clin Infect Dis Date: 2011-01-18 Impact factor: 9.079
Authors: Ye Ma; Decai Zhao; Lan Yu; Marc Bulterys; Matthew L Robinson; Yan Zhao; Zhihui Dou; Philippe Chiliade; Xiaoyu Wei; Fujie Zhang Journal: Clin Infect Dis Date: 2010-01-15 Impact factor: 9.079
Authors: Robert Gross; Scarlett L Bellamy; Bakgaki Ratshaa; Xiaoyan Han; Andrew P Steenhoff; Mosepele Mosepele; Gregory P Bisson Journal: Addiction Date: 2016-09-07 Impact factor: 6.526
Authors: Robert Gross; Scarlett L Bellamy; Jennifer Chapman; Xiaoyan Han; Jacqueline O'Duor; Steven C Palmer; Peter S Houts; James C Coyne; Brian L Strom Journal: JAMA Intern Med Date: 2013-02-25 Impact factor: 21.873